Publication | Closed Access
ctDNA-Guided Adjuvant Atezolizumab in Muscle-Invasive Bladder Cancer
32
Citations
15
References
2025
Year
Among patients with muscle-invasive bladder cancer, ctDNA-guided adjuvant therapy with atezolizumab led to significantly longer disease-free survival and overall survival than placebo. (Funded by F. Hoffmann-La Roche; IMvigor011 ClinicalTrials.gov number, NCT04660344.).
| Year | Citations | |
|---|---|---|
Page 1
Page 1